Search

Your search keyword '"Fraschini, G"' showing total 226 results
Start Over Author "Fraschini, G"
226 results on '"Fraschini, G"'

16. Short-Term Efficacy and Safety of Betamethasone Valerate 2.25 mg Medicated Plaster in Patients with Chronic Lateral Epicondylitis: Results of a Randomised, Double Blind, Placebo-controlled Study

Author

Bernasconi, S., primary, Causero, A., additional, Giaffreda, G., additional, Papalia, R., additional, Caruso, G., additional, Bonanno, G., additional, Sadile, F., additional, Fraschini, G., additional, Fortina, M., additional, Frizziero, A., additional, Chiarelli, N., additional, Salini, V., additional, Tarantino, U., additional, Voglino, N., additional, Castagna, A., additional, Grassi, F.A., additional, Rovati, S., additional, and Frangione, V., additional

Published
2019
Full Text
View/download PDF

20. Synthetic composite material useful for e.g. tissue repair, comprises first layer comprising organic material and having side walls and external surface, and second porous layer comprising inorganic material and having side walls

Author

PERETTI G, FRASCHINI G, DI GIANCAMILLO A, DOMENEGHINI C, DEPONTI D. R., SANNINO, Alessandro, GERVASO, FRANCESCA, SCALERA, FRANCESCA, Peretti, G, Fraschini, G, Sannino, Alessandro, Gervaso, Francesca, Scalera, Francesca, DI GIANCAMILLO, A, Domeneghini, C, and Deponti, D. R.

Published
2014

21. A tissue engineered osteochondral composite for cartilage repair: a large animal study

Author

Peretti, G. M., Sosio, C., Deponti, D., Melato, M., Di Giancamillo, A., Francesca Gervaso, Padmanabhan, S. Kunjalukkal, Domeneghini, C., Fraschini, G., Sannino, A., Peretti, Gm, Sosio, C., Deponti, D., Melato, M., Di Giancamillo, A., Gervaso, Francesca, Kunjalukkal Padmanabhan, S., Domeneghini, C., Fraschini, G., and Sannino, A.

Published
2012

24. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty

Author

Eriksson, Bi, Borris, Lc, Friedman, Rj, Haas, S, Huisman, Mv, Kakkar, Ak, Bandel, Tj, Beckmann, H, Muehlhofer, E, Misselwitz, F, Geerts, W, COLLABORATORS: Eriksson BI, RECORD1 Study G. r. o. u. p., Levine, M, Eriksson, H, Sandrgen, G, Wallin, J, Bode, C, Bassand, Jp, Lüscher, T, Angeras, U, Falk, A, Prins, M, Leizorovicz, A, Bounameaux, H, Larrey, D, Migge, A, Caviglia, H, Ceresetto, J, Cicchetti, A, D'Onofrio, A, Diaz, A, Mendler, H, Saa, J, Blombery, P, Chong, B, Gallus, A, Leahy, M, Salem, H, Bauer, N, Boehl, N, Freund, N, Hochreiter, J, Jakubek, M, Labek, G, Windhager, R, Zenz, P, Borms, T, Brabants, C, Colinet, J, de Rycke, J, Driesen, R, Gunst, P, Mortele, H, van Loon, L, Vandermeersch, E, Vanlommel, D, Queiroz, Rd, Fridman, M, Penedo, Jm, Schwartsmann, C, Abuzgaya, F, Belzile, E, Dobson, C, Fisher, W, Grosso, P, Mant, M, Pototschnik, R, Solymoss, S, Zalzal, P, Bittelman, S, Cordova, M, Reyes, A, Rocha, C, Toledo, D, Altschul, J, Fousek, J, Koudela, K, Kriz, Z, Lutonsky, M, Pach, M, Sedivy, P, Stehlik, J, Svagr, M, Svec, M, Borgwardt, Oa, Joergensen, P, Lassen, Mr, Lausten, G, Mikkelsen, S, Jokipii, P, Pesola, M, Waris, P, Debue, Jm, Forestier, C, Hennion, G, Lazard, T, Macaire, P, Maire, Jy, Marouan, A, Maschino, X, Matuszczak, Y, Moulinie, Jp, Osman, M, Peron, A, Pinson, Jj, Birkner, W, Buechler, M, Eulert, J, Fritsche, Hm, Guen, Kp, Halder, A, Horacek, T, Kiekenbeck, A, Kleinfeld, F, Krauspe, R, Kurth, A, Labs, K, Mittelme, W, Mouret, P, Muehlbauer, B, Quante, M, Schmelz, H, Wirth, T, Babis, G, Beldekos, A, Soukakos, P, Bucsi, L, Lenart, E, Mike, G, Sarvary, A, Shafiei, F, Szenbeni, A, Szendroi, M, Toth, J, Toth, K, Benkovich, V, Brenner, B, Dekel, S, Halperin, N, Hendel, D, Martinovich, U, Nyska, M, Salai, M, Borghi, B, Bosco, M, Castelli, C, Cherubino, P, Franchin, FRANCESCO MARIA, Fraschini, G, Greco, F, Grossi, P, Gusso, M, Landolfi, R, Leali, T, Lodigiani, C, Marinoni, E, Martorana, U, Massari, L, Melis, G, Miletto, A, Parise, P, Rinaldi, G, Riva, R, Silingardi, M, Porvaneckas, N, Smailys, A, Dijk, Cn, Nolte, Pa, Schuller, Hm, Slappendel, R, van der List JJ, Verheyen, Cc, Vis, Hm, Aarseth, O, Al Dekany, K, Borgen, P, Roenning, Re, Talsnes, O, Bednarek, A, Blacha, J, Deszczyski, J, Dutka, J, Gazdzik, T, Golec, E, Gorecki, A, Gusta, A, Krasicki, M, Kruczyski, J, Kusz, D, Kwiatkowsk, K, Mazurkiewi, S, Niedwiedzki, T, Pozowski, A, Skowronski, J, Swaton, R, Synder, M, Tkaczyk, T, Knapec, L, Lisy, M, Stasko, I, Engelbrecht, J, Myburgh, H, van Zyl, L, Canosa Sevillano, R, Delgado, A, Diaz Almodovar JL, Giros Torres, J, Granero, X, Gomar, F, Lecumberri Villamedi, R, Navarro Quiles, A, Otero Fernandez, R, Paz Jimenez, J, Peidro Garces, L, Pino Minguez, J, Puig Verdier, L, Ruiz Sanchez, A, Salvador, A, Valdes Casas JC, Laestander, H, Liliequist, J, Lind, S, Paulsson, B, Wykman, A, Altintas, F, Esemelli, T, Karatosun, V, Togrul, E, Tozun, R, Allmacher, D, Buettner, C, Colwell C., Jr, Friedman, R, Gimbel, J, Jove, M, King, R, Martin, K, Murray, R, Peters P., Jr, Sledge, S, Swappach, J, Taunton O., Jr, Ward, J., Eriksson BI, Borris LC., Friedman RJ., Haas S., Huisman MV., Kakkar AK., Bandel TJ., Beckmann H., Muehlhofer E, Misselwitz F., Geerts W., RECORD 1 Study Group, and Borghi B.

Subjects
Male, medicine.medical_treatment, Arthroplasty, Replacement, Hip, Replacement, Adolescent, Adult, Aged, Aged, 80 and over, Anticoagulants, adverse effects/therapeutic use, Arthroplasty, Hip, Double-Blind Method, Enoxaparin, adverse effects/therapeutic use, Factor Xa, antagonists /&/ inhibitors, Female, Humans, Male, Middle Aged, Morpholines, adverse effects/therapeutic use, Pulmonary Embolism, epidemiology/prevention /&/ control, Thiophenes, adverse effects/therapeutic use, Venous Thromboembolism, mortality/prevention /&/ control, Venous Thrombosis, epidemiology/prevention /&/ control, Rivaroxaban, 80 and over, antagonists /&/ inhibitors, Aged, 80 and over, Venous Thrombosis, medicine.diagnostic_test, RIVAROXABAN, ENOXAPARIN, THROMBOPROFILAXIS, HIP, ARTHROPLASTY, Anticoagulant, General Medicine, Venous Thromboembolism, Middle Aged, mortality/prevention /&/ control, Thrombosis, Pulmonary embolism, adverse effects/therapeutic use, Anesthesia, Factor Xa, Female, Enoxaparin sodium, medicine.drug, Adult, medicine.medical_specialty, Adolescent, medicine.drug_class, thromboprophylaxis, venography, bleeding, Morpholines, Venography, Low molecular weight heparin, Thiophenes, Arthroplasty, Double-Blind Method, medicine, Humans, Enoxaparin, Aged, Hip, business.industry, Anticoagulants, medicine.disease, Surgery, business, Pulmonary Embolism, Factor Xa Inhibitors
Abstract

BACKGROUND: This phase 3 trial compared the efficacy and safety of rivaroxaban, an oral direct inhibitor of factor Xa, with those of enoxaparin for extended thromboprophylaxis in patients undergoing total hip arthroplasty. METHODS: In this randomized, double-blind study, we assigned 4541 patients to receive either 10 mg of oral rivaroxaban once daily, beginning after surgery, or 40 mg of enoxaparin subcutaneously once daily, beginning the evening before surgery, plus a placebo tablet or injection. The primary efficacy outcome was the composite of deep-vein thrombosis (either symptomatic or detected by bilateral venography if the patient was asymptomatic), nonfatal pulmonary embolism, or death from any cause at 36 days (range, 30 to 42). The main secondary efficacy outcome was major venous thromboembolism (proximal deep-vein thrombosis, nonfatal pulmonary embolism, or death from venous thromboembolism). The primary safety outcome was major bleeding. RESULTS: A total of 3153 patients were included in the superiority analysis (after 1388 exclusions), and 4433 were included in the safety analysis (after 108 exclusions). The primary efficacy outcome occurred in 18 of 1595 patients (1.1%) in the rivaroxaban group and in 58 of 1558 patients (3.7%) in the enoxaparin group (absolute risk reduction, 2.6%; 95% confidence interval [CI], 1.5 to 3.7; P

Published
2008

25. Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement

Author

Eriksson, B. I., Borris, L., Dahl, O. E., Haas, S., Huisman, M. V., Kakkar, A. K., Misselwitz, F., Kalebo, P., Breyer, H. -G., Bounameaux, H., Leizorovicz, A., Angeras, U., Falk, A., Prins, M., Zachrisson, B., Eriksson, H., Sandgren, G., Wallin, J., Engel, A., Hochreiter, J., Niessner, H., Driesen, R., Horlyck, E., Jorgensen, P. S., Lassen, M., Delecroix, M., Hayek, E., Le Pelley, E., Birkner, W., Fritsche, H. -M., Gunther, K. -P., Halder, A., Kleinfeld, F., Kurth, A., Mouret, P., Brenner, B., Dekel, S., Halperin, N., Martinovich, U., Ageno, W., Fraschini, G., Lodigiani, C., Parise, P., Silingardi, M., Slappendel, R., van der Vis, H., Verburg, A., Aarseth, O., Hovick, O., Hovind, H., Bednarek, A., Blancha, J., Kwiatkowski, K., Mazurkiewicz, S., Niedzwiedski, T., Skowronski, J., Castellet, E., Gomar, F., Granero, X., Peidro, L., Edshage, B., Lind, S., Wykman, A., and Cohen, A.

Subjects
Male, medicine.drug_mechanism_of_action, medicine.medical_treatment, Deep vein, Arthroplasty, Replacement, Hip, Knee replacement, law.invention, Postoperative Complications, Randomized controlled trial, Rivaroxaban, law, Aged, 80 and over, Venous Thrombosis, medicine.diagnostic_test, Total hip replacement, Hematology, Middle Aged, Thrombosis, Pulmonary embolism, Direct Factor Xa inhibitor, medicine.anatomical_structure, Anesthesia, Female, Venous thromboembolism, medicine.drug, Adult, medicine.medical_specialty, Morpholines, Factor Xa Inhibitor, Venography, Hemorrhage, Thiophenes, Oral anticoagulant, Prophylaxis, Double-Blind Method, Thromboembolism, medicine, Humans, Enoxaparin, Aged, Dose-Response Relationship, Drug, business.industry, Anticoagulants, medicine.disease, Surgery, business, Pulmonary Embolism, Factor Xa Inhibitors
Abstract

Summary. Background: Joint replacement surgery is an appropriate model for dose-ranging studies investigating new anticoagulants. Objectives: To assess the efficacy and safety of a novel, oral, direct factor Xa (FXa) inhibitor – BAY 59-7939 – relative to enoxaparin in patients undergoing elective total hip replacement. Methods: In this double-blind, double-dummy, dose-ranging study, patients were randomized to oral BAY 59-7939 (2.5, 5, 10, 20, or 30 mg b.i.d.), starting 6–8 h after surgery, or s.c. enoxaparin 40 mg once daily, starting on the evening before surgery. Treatment was continued until mandatory bilateral venography was performed 5–9 days after surgery. Results: Of 706 patients treated, 548 were eligible for the primary efficacy analysis. The primary efficacy endpoint was the incidence of any deep vein thrombosis, non-fatal pulmonary embolism, and all-cause mortality; rates were 15%, 14%, 12%, 18%, and 7% for BAY 59-7939 2.5, 5, 10, 20, and 30 mg b.i.d., respectively, compared with 17% for enoxaparin. The primary efficacy analysis did not demonstrate any significant trend in dose–response relationship for BAY 59-7939. The primary safety endpoint was major, postoperative bleeding; there was a significant increase in the frequency of events with increasing doses of BAY 59-7939 (P = 0.045), but no significant differences between individual BAY 59-7939 doses and enoxaparin. Conclusions: When efficacy and safety were considered together, the oral, direct FXa inhibitor BAY 59-7939, at 2.5–10 mg b.i.d., compared favorably with enoxaparin for the prevention of venous thromboembolism in patients undergoing elective total hip replacement.

Published
2006

42. Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer.

Author

Holmes, F A, primary, Madden, T, additional, Newman, R A, additional, Valero, V, additional, Theriault, R L, additional, Fraschini, G, additional, Walters, R S, additional, Booser, D J, additional, Buzdar, A U, additional, Willey, J, additional, and Hortobagyi, G N, additional

Published
1996
Full Text
View/download PDF

50. Clinical course of patients with breast cancer with ten or more positive nodes who were treated with doxorubicin-containing adjuvant therapy.

Author

Buzdar, Aman U., Kau, Shu-Wan, Hortobagyi, Gabriel N., Ames, Frederick C., Holmes, Frankie A., Fraschini, Giuseppe, Hug, Verena, Theriault, Richard L., McNeese, Marsha D., Singletary, S. Eva, Buzdar, A U, Kau, S W, Hortobagyi, G N, Ames, F C, Holmes, F A, Fraschini, G, Hug, V, Theriault, R L, McNeese, M D, and Singletary, S E

Published
1992
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results